Essays · The Hillman Letter · Long-form
Long-form essays on FDA, frontier therapeutics, and capital. Operator notes from inside the work.
Weekly long-form essays on FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Subscribe at thehillmanletter.substack.com.
Why most exosome programs choose the wrong FDA pathway and what that costs them. Published essay covering minimal manipulation, homologous use, and the BLA route.
Why patient capital fits FDA-regulated biotech better than venture timelines. Structuring investments around regulatory milestones rather than fundraising rounds.
Six documentation patterns that show up before federal healthcare enforcement. Practical content for compliance officers and in-house counsel.
Targeted Osmotic Lysis explainer. The mechanism behind TOL, the an academic medical foundation partnership, and what it means for chemotherapy-free oncology.
The Dallas biotech ecosystem, the operator network, and why this is the place to build regulated healthcare today.
The Hillman Letter weekly essays. thehillmanletter.substack.com
Long-form LinkedIn articles. linkedin.com/in/andrew-hillman-dallas
Coverage and podcast appearances logged at andrew-hillman.com/coverage.
For media or interview requests: ajhillman@gmail.com.